Opportunities and challenges lay ahead along the continuum from traditional to hybrid studies, a transition which requires additional infrastructure and...
Opportunities and challenges lay ahead along the continuum from traditional to hybrid studies, a transition which requires additional infrastructure and associated risks to data protection and patient safety.
Opportunities and challenges lay ahead along the continuum from traditional to hybrid studies, a transition which requires additional infrastructure and associated risks to data protection and patient...
Data sources have grown exponentially over recent years, adding significant complexity to the lifecycle of studies and increasing risks to timelines and...
Data sources have grown exponentially over recent years, adding significant complexity to the lifecycle of studies and increasing risks to timelines and budgets.
Are eClinical technologies and industry initiatives helping improve site and sponsor-CRO collaboration and creating a competitive edge through improved clinical...
Are eClinical technologies and industry initiatives helping improve site and sponsor-CRO collaboration and creating a competitive edge through improved clinical trial performance?
Choosing where to conduct a global clinical trial is a critical strategic decision that can impact an entire drug development program. When it comes to planning...
Choosing where to conduct a global clinical trial is a critical strategic decision that can impact an entire drug development program. When it comes to planning country selection, Fortuna Eruditis Favet (“fortune favors the prepared mind”).
Choosing where to conduct a global clinical trial is a critical strategic decision that can impact an entire drug development program. When it comes to planning country selection, Fortuna Eruditis...
Sites are dynamic environments, and new technology and industry initiatives are an important complement to the critical need for relationship building and...
Sites are dynamic environments, and new technology and industry initiatives are an important complement to the critical need for relationship building and maintenance. But are they helping improve sponsors and CROs collaboration with sites, or enabling them to become more competitive through improved clinical trial performance?
Sites are dynamic environments, and new technology and industry initiatives are an important complement to the critical need for relationship building and maintenance. But are they helping...
ICON presents on the value of using business intelligence in study startup to spot risk factors and bottlenecks that can disrupt cycle times and budgets.
Site selection is pivotal to the successful execution of clinical trials, which are not only long and bureaucratic, but are also experiencing diminishing...
Site selection is pivotal to the successful execution of clinical trials, which are not only long and bureaucratic, but are also experiencing diminishing returns.
Robotic Process Automation (RPA) represents an opportunity to quickly automate repetitive tasks and free employees to work on more value-adding tasks. There are...
Robotic Process Automation (RPA) represents an opportunity to quickly automate repetitive tasks and free employees to work on more value-adding tasks. There are a number of repetitive, time-consuming tasks that if automated would improve Clinical Data Manager daily operations. RPA can be scheduled or triggered to execute and run in an unattended fashion.
Robotic Process Automation (RPA) represents an opportunity to quickly automate repetitive tasks and free employees to work on more value-adding tasks. There are a number of repetitive, time-consuming...
Metrics are critical to efforts for reining in clinical trials that are either poorly initiated or have incurred unforeseen events which place the original...
Metrics are critical to efforts for reining in clinical trials that are either poorly initiated or have incurred unforeseen events which place the original timelines and/or budgets at risk of overages. They also drive competitive performance among those organizations performing trials.
Metrics are critical to efforts for reining in clinical trials that are either poorly initiated or have incurred unforeseen events which place the original timelines and/or budgets at risk...
